The sustainability of the biopharma sector depends on a continual flow of new startups to both feed Big Pharma’s pipelines and to create the next generation of emerging mid-cap companies. At the BioPharma America conference this week, several panelists asserted that we aren’t starting enough new companies to resupply the “corporate pipeline” for future acquisitions, and that this was leading to fewer maturing mid-cap biotech biotech companies and a dearth of compelling biotech assets.
